IM Cannabis (IMCC) Competitors $2.27 +0.03 (+1.34%) Closing price 03:54 PM EasternExtended Trading$2.29 +0.02 (+0.88%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMCC vs. QNTM, ATNM, UNCY, ANVS, PRLD, SLGL, STTK, VTVT, MAAQ, and ABVCShould you be buying IM Cannabis stock or one of its competitors? The main competitors of IM Cannabis include Quantum Biopharma (QNTM), Actinium Pharmaceuticals (ATNM), Unicycive Therapeutics (UNCY), Annovis Bio (ANVS), Prelude Therapeutics (PRLD), Sol-Gel Technologies (SLGL), Shattuck Labs (STTK), vTv Therapeutics (VTVT), Mana Capital Acquisition (MAAQ), and ABVC BioPharma (ABVC). These companies are all part of the "pharmaceutical products" industry. IM Cannabis vs. Its Competitors Quantum Biopharma Actinium Pharmaceuticals Unicycive Therapeutics Annovis Bio Prelude Therapeutics Sol-Gel Technologies Shattuck Labs vTv Therapeutics Mana Capital Acquisition ABVC BioPharma Quantum Biopharma (NASDAQ:QNTM) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership. Is QNTM or IMCC more profitable? Quantum Biopharma has a net margin of 0.00% compared to IM Cannabis' net margin of -4.19%. IM Cannabis' return on equity of -59.80% beat Quantum Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Quantum BiopharmaN/A -270.22% -131.87% IM Cannabis -4.19%-59.80%-5.15% Which has more risk and volatility, QNTM or IMCC? Quantum Biopharma has a beta of 0.71, meaning that its share price is 29% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.2, meaning that its share price is 120% more volatile than the S&P 500. Which has better valuation & earnings, QNTM or IMCC? IM Cannabis has higher revenue and earnings than Quantum Biopharma. IM Cannabis is trading at a lower price-to-earnings ratio than Quantum Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQuantum BiopharmaN/AN/A-$14.20M-$14.02-1.19IM Cannabis$39.44M0.30-$7.72M-$0.54-4.20 Does the media favor QNTM or IMCC? In the previous week, Quantum Biopharma had 1 more articles in the media than IM Cannabis. MarketBeat recorded 2 mentions for Quantum Biopharma and 1 mentions for IM Cannabis. IM Cannabis' average media sentiment score of 1.87 beat Quantum Biopharma's score of 0.94 indicating that IM Cannabis is being referred to more favorably in the news media. Company Overall Sentiment Quantum Biopharma Positive IM Cannabis Very Positive Do institutionals & insiders hold more shares of QNTM or IMCC? 1.2% of Quantum Biopharma shares are owned by institutional investors. Comparatively, 7.7% of IM Cannabis shares are owned by institutional investors. 8.5% of Quantum Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryIM Cannabis beats Quantum Biopharma on 8 of the 12 factors compared between the two stocks. Get IM Cannabis News Delivered to You Automatically Sign up to receive the latest news and ratings for IMCC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMCC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMCC vs. The Competition Export to ExcelMetricIM CannabisMED PRODUCTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.92M$10.61B$5.74B$9.78BDividend YieldN/A1.86%4.40%4.04%P/E Ratio-4.2021.2030.8326.39Price / Sales0.3031.79382.9086.63Price / CashN/A24.9137.7259.11Price / Book4.053.5110.106.62Net Income-$7.72M$210.11M$3.26B$265.42M7 Day PerformanceN/A5.86%3.90%3.58%1 Month Performance-19.22%11.12%3.73%0.46%1 Year Performance-23.31%-7.57%37.68%19.41% IM Cannabis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMCCIM Cannabis1.2056 of 5 stars$2.27+1.3%N/A-23.5%$11.92M$39.44M-4.20340Positive NewsGap UpQNTMQuantum BiopharmaN/A$18.03-12.5%N/AN/A$52.47MN/A-1.29N/AGap DownATNMActinium Pharmaceuticals2.3985 of 5 stars$1.65-3.5%$4.50+172.7%-15.6%$51.47MN/A-1.1930UNCYUnicycive Therapeutics2.5331 of 5 stars$4.07-0.2%$60.00+1,374.2%+16.4%$51.45M$680K-0.999Trending NewsHigh Trading VolumeANVSAnnovis Bio2.3554 of 5 stars$2.60-3.4%$18.00+592.6%-74.7%$50.66MN/A-1.273PRLDPrelude Therapeutics2.8898 of 5 stars$0.89-5.4%$4.00+347.8%-77.7%$50.56M$7M-0.54120SLGLSol-Gel Technologies0.7529 of 5 stars$17.74+10.2%N/A+288.4%$49.42M$23.93M-14.4250STTKShattuck Labs3.5022 of 5 stars$1.03+1.0%$7.00+579.6%-71.7%$49.34M$5.72M-0.85100News CoverageVTVTvTv Therapeutics2.0854 of 5 stars$15.24-1.3%$35.50+133.0%-8.9%$48.68M$17K-4.889Positive NewsHigh Trading VolumeMAAQMana Capital AcquisitionN/A$3.72+2.5%N/A-38.6%$48.67MN/A0.001ABVCABVC BioPharma0.6471 of 5 stars$2.85-8.9%N/A+314.0%$48.40M$391.24K-16.7630 Related Companies and Tools Related Companies QNTM Competitors ATNM Competitors UNCY Competitors ANVS Competitors PRLD Competitors SLGL Competitors STTK Competitors VTVT Competitors MAAQ Competitors ABVC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMCC) was last updated on 8/27/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IM Cannabis Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share IM Cannabis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access